MIAMI BEACH, Fla., April 06, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 2nd, 2026, by AirSculpt Technologies, Inc. (NASDAQ:AIRS), please note that the Company determined that a one-time non-cash adjustment related to the closure of its London facility was inaccurate in the calculation of Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted Net (Loss)/Income. The updated release reflects the updated figures.
AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the fourth quarter and twelve months ended December 31, 2025.
Yogi Jashnani, Chief Executive Officer, stated: “In the fourth quarter, we delivered sequential improvement in same store sales versus the first nine months of the year. During 2025, we took significant steps to enhance our business approach and team. We added talent, improved business processes, implemented a new go-to-market strategy, and added new procedures that expanded our market potential."
"The results of this work are already evident,” continued Mr Jashnani. “We entered fiscal 2026 with same-store sales turning positive in February and enhanced financial flexibility to fuel our growth. I'm pleased with our team's unwavering commitment and excited about what lies ahead. AirSculpt is scaled, trusted and strongly positioned at the intersection of aesthetics and GLP-1’s. I'm confident our strategy positions us to create meaningful value for our shareholders." concluded Mr. Jashnani.
Fourth Quarter 2025 Results
- Case volume was 2,604 for the fourth quarter of 2025, representing a 15.0% decline from the fiscal year 2024 fourth quarter case volume of 3,064;
- Revenue declined 14.6% to $33.4 million from $39.2 million in the fiscal year 2024 fourth quarter;
- Net loss for the quarter was $1.3 million compared to net loss of $5.0 million in the fiscal year 2024 fourth quarter; and
- Adjusted EBITDA was $(0.1) million compared to $1.9 million in the fiscal year 2024 fourth quarter.
Full Year 2025 Results
- Case volume was 11,852, a decline of 15.6% from the full fiscal year 2024 case volume of 14,036;
- Revenue declined 15.8% to $151.8 million from $180.4 million in the full fiscal year 2024;
- Net loss was $11.7 million compared to $8.0 million in the full fiscal year 2024; and
- Adjusted EBITDA was $12.5 million compared to $21.0 million in the full fiscal year 2024.
2026 Outlook
The Company projects full year 2026 revenue and adjusted EBITDA guidance as follows:
- Revenue of approximately $151 to $157 million
- Adjusted EBITDA of approximately $15 to $17 million
The Company expects first quarter 2026 revenue of $38.5 to $39.5 million representing same-store revenue of approximately flat at the midpoint.
For additional information on forward-looking statements, see the section titled "Forward-Looking Statements" below.
Debt & Liquidity
As of December 31, 2025, the Company had $8.4 million in cash and cash equivalents, with $5.0 million of borrowing capacity under its revolving credit facility. Additionally, gross debt was approximately $56.0 million. During the 2026 first quarter, the Company raised an additional $14.8 million from the at-the-market offering program and paid down $11.0 million of debt, resulting in gross debt of approximately $45.0 million as of the 2026 first quarter. The Company remains in compliance with all debt covenants.
Conference Call Information
AirSculpt will hold a conference call today, April 2, 2026 at 8:30 am (Eastern Time). The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13758597 or by visiting the link below to request a return call for instant telephone access to the event.
https://callme.viavid.com/viavid/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9MTM3MjUxMTYmaD10cnVlJmluZm89Y29tcGFueSZyPXRydWUmQj02
The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.airsculpt.com. A replay of the webcast will be available for approximately 90 days following the call.
To learn more about AirSculpt, please visit the Company's website at https://investors.airsculpt.com. AirSculpt uses its website as a channel of distribution for material Company information. Financial and other material information regarding AirSculpt is routinely posted on the Company's website and is readily accessible.
About AirSculpt
AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal U.S. securities laws. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include projections of our future financial performance (including in particular our projected 2026 revenue and adjusted EBITDA), our anticipated growth strategies, and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. You are cautioned that there are important risks and uncertainties, many of which are beyond our control, that could cause our actual results, level of activity, performance, or achievements to differ materially from the projected results, level of activity, performance or achievements that are expressed or implied by such forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements, including those factors discussed in the section titled “Risk Factors” in our Annual Report on Form 10-K.
Our future results could be affected by a variety of other factors, including, but not limited to, inability to sell equity or other securities in the future at a time when we might otherwise wish to effect sales; inability to raise capital on commercially reasonable terms, if at all; the risk that any future financings may dilute our stockholders or restrict our business; failure to stabilize same-store performance; not being able to optimize our marketing investment, go-to-market strategy and sales process; not having the ability to expand our financing options for consumers; being unsuccessful in further product innovations; failure to operate centers in a cost-effective manner; increased operating expenses due to rising inflation; increased competition in the weight loss and obesity solutions market, including as a result of the recent regulatory approval, increased market acceptance, availability and customer awareness of weight-loss drugs; shortages or quality control issues with third-party manufacturers or suppliers; competition for surgeons; litigation or medical malpractice claims; inability to protect the confidentiality of our proprietary information; changes in the laws governing the corporate practice of medicine or fee-splitting; changes in regulatory and macroeconomic conditions, including inflation and the threat of recession, economic and other conditions of the states and jurisdictions where our facilities are located; and business disruption or other losses from natural disasters, war, pandemic, terrorist acts or political unrest.
The risk factors discussed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K and in other filings we make from time to time with the SEC could cause our results to differ materially from those expressed in the forward-looking statements made in this press release.
There also may be other risks and uncertainties that are currently unknown to us or that we are unable to predict at this time.
Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Forward-looking statements represent our estimates and assumptions only as of the date they were made, which are inherently subject to change, and we are under no duty and we assume no obligation to update any of these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated after the date of this press release to conform our prior statements to actual results or revised expectations, except as required by law. Given these uncertainties, investors should not place undue reliance on these forward-looking statements.
Use of Non-GAAP Financial Measures
The Company reports financial results in accordance with generally accepted accounting principles in the United States (“GAAP”), however, the Company believes the evaluation of ongoing operating results may be enhanced by a presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted Net Income per Share, which are non-GAAP financial measures. Although the Company provides guidance for Adjusted EBITDA, it is not able to provide guidance for net income, the most directly comparable GAAP measure. Certain elements of the composition of net income, including equity-based compensation, are not predictable, making it impractical for us to provide guidance on net income or to reconcile our Adjusted EBITDA guidance to net income without unreasonable efforts. For the same reasons, the Company is unable to address the probable significance of the unavailable information regarding net income, which could be material to future results.
These non-GAAP financial measures are not intended to replace financial performance measures determined in accordance with GAAP. Rather, they are presented as supplemental measures of the Company's performance that management believes may enhance the evaluation of the Company's ongoing operating results. These non-GAAP financial measures are not presented in accordance with GAAP, and the Company’s computation of these non-GAAP financial measures may vary from similar measures used by other companies. These measures have limitations as an analytical tool and should not be considered in isolation or as a substitute or alternative to revenue, net income, operating income, cash flows from operating activities, total indebtedness or any other measures of operating performance, liquidity or indebtedness derived in accordance with GAAP.
Selected Consolidated Financial Data
(Dollars in thousands, except shares and per share amounts)
Three Months Ended
December 31, Twelve Months Ended
December 31, 2025
2024
2025
2024
Revenue$33,442 $39,178 $151,818 $180,350 Operating expenses: Cost of service 13,675 16,689 61,690 71,149 Selling, general and administrative(1) 18,216 23,355 82,180 98,880 Depreciation and amortization 3,076 3,195 12,781 11,888 Loss on impairment of long-lived assets (2) (2,670) 12 4,575 16 Cost related to closing location, net (3) 2,152 — 2,152 — Total operating expenses 34,449 43,251 163,378 181,933 Loss from operations (1,007) (4,073) (11,560) (1,583)Interest expense, net 1,484 1,609 6,078 6,247 Pre-tax net loss (2,491) (5,682) (17,638) (7,830)Income tax (benefit)/expense (3,774) (706) (5,971) 188 Net income/(loss)$1,283 $(4,976) $(11,667) $(8,018) Income/(loss) per share of common stock Basic$0.02 $(0.09) $(0.19) $(0.14)Diluted$0.02 $(0.09) $(0.19) $(0.14)Weighted average shares outstanding Basic 63,278,594 58,121,431 60,450,769 57,688,906 Diluted 68,216,681 58,121,431 60,450,769 57,688,906
Selected Financial and Operating Data
(Dollars in thousands, except per case amounts)
December 31,
2025 December 31,
2024Balance Sheet Data (at period end): Cash and cash equivalents$8,449 $8,235Total current assets 15,456 17,117Total assets$187,304 $212,781 Current portion of long-term debt$5,460 $4,250Deferred revenue and patient deposits 1,871 1,169Total current liabilities 27,902 28,949Long-term debt, net 50,585 65,456Revolving credit funds payable — 5,000Total liabilities$99,592 $134,593 Total stockholders’ equity$87,712 $78,188
December 31, Twelve Months Ended
December 31, 2025 2024 2025 2024 Cash Flow Data: Net cash provided by (used in): Operating activities$(2,531) $2,713 $3,096 $11,350 Investing activities (58) (3,528) (2,404) (14,007)Financing activities 5,633 3,078 (478) 630
December 31, Twelve Months Ended
December 31, 2025 2024 2025 2024 Other Data: Number of facilities 31 32 31 32 Number of total procedure rooms 65 67 65 67 Cases 2,604 3,064 11,852 14,036 Revenue per case$12,843 $12,787 $12,809 $12,849 Adjusted EBITDA (1)$(130) $1,913 $12,499 $20,959 Adjusted EBITDA margin (2) (0.4)% 4.9% 8.2% 11.6%
Selected Financial and Operating Data
(Dollars in thousands, except per case amounts)
Three Months Ended
December 31, Twelve Months Ended
December 31, 2025
2024
2025
2024
Same-center Information (1): Cases 2,345 2,879 10,670 13,689Case growth(18.5)% N/A (22.1)% N/ARevenue per case$12,891 $12,797 $12,798 $12,781Revenue per case growth 0.7% N/A 0.1% N/ANumber of facilities 31 31 31 31Number of total procedure rooms 65 65 65 65
For the twelve months ended December 31, 2025 and 2024, we define same-center case and revenue growth as the growth in each of our cases and revenue at facilities that were owned and operated during the twelve months ended December 31, 2025 and 2024, respectively. At facilities that were not owned or operated for the entirety of the prior year period, the current year period has been pro-rated to reflect only growth experienced during the portion of the twelve months ended December 31, 2025 in which such facilities were owned and operated during the twelve months ended December 31, 2024. We define same-center facilities and procedure rooms based on if a facility was owned or operated as of December 31, 2024. Beginning September 30, 2025, we have excluded the London facility from all periods presented due to the closure of the facility.
Reconciliation of Non-GAAP Financial Measures
(Dollars in thousands)
We report our financial results in accordance with GAAP, however, management believes the evaluation of our ongoing operating results may be enhanced by a presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted Net Income per Share, which are non-GAAP financial measures.
We define Adjusted EBITDA as net income/(loss) excluding depreciation and amortization, net interest expense, income tax (benefit)/expense, restructuring and related severance costs, loss on impairment of long-lived assets, costs related to closing facility and equity-based compensation.
We define Adjusted Net Income as net income/(loss) excluding restructuring and related severance costs, loss on impairment of long-lived assets, cost related to closing facility equity-based compensation and the tax effect of these adjustments.
We include Adjusted EBITDA and Adjusted Net Income because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA and Adjusted Net Income each to be an important measure because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. Adjusted EBITDA has limitations as an analytical tool including: (i) Adjusted EBITDA does not include results from equity-based compensation and (ii) Adjusted EBITDA does not reflect interest expense on our debt or the cash requirements necessary to service interest or principal payments. Adjusted Net Income has limitations as an analytical tool because it does not include results from equity-based compensation.
We define Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of revenue. We define Adjusted Net Income per Share as Adjusted Net Income divided by weighted average basic and diluted shares. We included Adjusted EBITDA Margin and Adjusted Net Income per Share because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA Margin and Adjusted Net Income per Share to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis.
The following table reconciles Adjusted EBITDA and Adjusted EBITDA Margin to net (loss)/income, the most directly comparable GAAP financial measure:
Three Months EndedDecember 31, Twelve Months Ended
December 31, 2025 2024 2025 2024 Net income/(loss)$1,283 $(4,976) $(11,667) $(8,018)Plus Equity-based compensation(1) (1,385) 2,240 2,331 3,762 Restructuring and related severance costs (296) 539 2,220 6,026 Depreciation and amortization 3,076 3,195 12,781 11,888 Loss on impairment of long-lived assets (2) (2,670) 12 4,575 16 Cost related to closing location, net (3) 2,152 — 2,152 — Litigation settlements(4) — — — 850 Interest expense, net 1,484 1,609 6,078 6,247 Income tax (benefit)/expense (3,774) (706) (5,971) 188 Adjusted EBITDA$(130) $1,913 $12,499 $20,959 Adjusted EBITDA Margin (0.4%) 4.9% 8.2% 11.6%
The following table reconciles Adjusted Net Income and Adjusted Net Income per Share to net income/(loss), the most directly comparable GAAP financial measure:
Three Months EndedDecember 31, Twelve Months Ended
December 31, 2025 2024 2025 2024 Net income/(loss)$1,283 $(4,976) $(11,667) $(8,018)Plus Equity-based compensation(1) (1,385) 2,240 2,331 3,762 Restructuring and related severance costs (296) 539 2,220 6,026 Loss on impairment of long-lived assets (2) (2,670) 12 4,575 16 Cost related to closing location, net (3) 2,152 — — 2,152 — Litigation settlements(4) — — — — 850 Tax effect of adjustments(5) (82) (2,267) (2,932) (1,271)Adjusted net income$(998) $(4,452) $(3,321) $1,365 Adjusted net income (loss) per share of common stock (6) Basic$(0.02) $(0.08) $(0.05) $0.02 Diluted$(0.02) $(0.08) $(0.05) $0.02 Weighted average shares outstanding Basic 63,278,594 58,121,431 60,450,769 57,688,906 Diluted 63,278,594 58,121,431 60,450,769 58,281,133
Investor Contact
Allison Malkin
ICR, Inc.
[email protected]